Discounted Cash Flow
Bioventus Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2019 | $340.1m | $6.9m | $40.2m | 2.0% | — |
| 2020 | $321.2m (-5.6%) | $16.4m (139.5%) | $68.1m (69.4%) | 5.1% (153.7%) | — |
| 2021 | $430.9m (34.2%) | $19.4m (18.1%) | $15.6m (-77.1%) | 4.5% (-12.0%) | $-0.11 |
| 2022 | $512.1m (18.8%) | $-158.7m (-919.1%) | $-23.6m (-250.9%) | -31.0% (-789.2%) | $-1.70 (-1445.5%) |
| 2023 | $512.3m (0.0%) | $-156.2m (1.6%) | $10.2m (143.1%) | -30.5% (1.6%) | $-1.54 (9.4%) |
| 2024 | $573.3m (11.9%) | $-33.5m (78.5%) | $37.8m (272.3%) | -5.9% (80.8%) | $-0.52 (66.2%) |
| 2025 | $568.1m (-0.9%) | $22.7m (167.8%) | $72.1m (90.8%) | 4.0% (168.4%) | $0.34 (165.4%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.